These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6254782)

  • 21. Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat.
    Bardo MT; Bhatnagar RK; Gebhart GF
    Brain Res; 1983 Dec; 289(1-2):223-34. PubMed ID: 6318895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone-induced opiate receptor supersensitivity.
    Zukin RS; Sugarman JR; Fitz-Syage ML; Gardner EL; Zukin SR; Gintzler AR
    Brain Res; 1982 Aug; 245(2):285-92. PubMed ID: 6289965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic opioid antagonist treatment: assessment of receptor upregulation.
    Yoburn BC; Sierra V; Lutfy K
    Eur J Pharmacol; 1989 Nov; 170(3):193-200. PubMed ID: 2559854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone.
    France CP; de Costa BR; Jacobson AE; Rice KC; Woods JH
    J Pharmacol Exp Ther; 1990 Feb; 252(2):600-4. PubMed ID: 2156055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-dimensional analyses of behavior in mice treated with naltrexone.
    Ukai M; Kameyama T
    Physiol Behav; 1985 Feb; 34(2):311-3. PubMed ID: 2987990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth retardation in young mice treated with d1-methadone.
    Crofford M; Smith AA
    Science; 1973 Sep; 181(4103):947-9. PubMed ID: 4730446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF; Nishimura S; Goodman RR; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of naltrexone on the development of physical dependence on morphine.
    Bhargava HN
    Eur J Pharmacol; 1978 Aug; 50(3):193-202. PubMed ID: 567585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid antagonist-induced regulation of organ development.
    Zagon IS; McLaughlin PJ
    Physiol Behav; 1985 Apr; 34(4):507-11. PubMed ID: 4011730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Morphine antagonists (pentazocine, nalorphine, naloxone and buprenophine)].
    Fournier T; Besserve P; Lefèvre P; Lephay A; Ossart M
    Cah Anesthesiol; 1988 May; 36(3):223-34. PubMed ID: 2840178
    [No Abstract]   [Full Text] [Related]  

  • 31. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic blockade of opiate receptors: influence on reproduction and body weight in female rats.
    Pfeiffer DG; Nikolarakis KE; Pfeiffer A
    Neuropeptides; 1984 Dec; 5(1-3):279-82. PubMed ID: 6099513
    [No Abstract]   [Full Text] [Related]  

  • 33. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
    Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naloxone blockade of (-)pentazocine-induced changes in auditory function.
    Sahley TL; Musiek FE; Nodar RH
    Ear Hear; 1996 Aug; 17(4):341-53. PubMed ID: 8862972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):322-30. PubMed ID: 8229759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
    White DA; Holtzman SG
    J Pharmacol Exp Ther; 2005 Jul; 314(1):374-82. PubMed ID: 15843500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of μ- and δ-opioid receptor function in the rewarding effect of (±)-pentazocine.
    Mori T; Itoh T; Yoshizawa K; Ise Y; Mizuo K; Saeki T; Komiya S; Masukawa D; Shibasaki M; Suzuki T
    Addict Biol; 2015 Jul; 20(4):724-32. PubMed ID: 25065832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quaternary opiate antagonists lower blood pressure and inhibit leucine-enkephalin responses.
    Giles T; Sander G; Merz H
    Eur J Pharmacol; 1983 Nov; 95(3-4):247-52. PubMed ID: 6197313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morphine, saline and naltrexone discrimination in morphine-treated pigeons.
    France CP; Woods JH
    J Pharmacol Exp Ther; 1987 Jul; 242(1):195-202. PubMed ID: 3612524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.